Evaluation of optimal dosing conditions for GLP-1 analogue NNC0113-0987 when administered orally in healthy male subjects
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2015
Price : $35 *
At a glance
- Drugs NN 9926 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 25 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 27 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.
- 27 Mar 2014 New trial record